Apply This IPO

Best Margin

Zero Brokerage

24*7 Customer Support.

Fastest mobile support

---

Apply with Angel One

Apply with Zerodha

Pre-Apply with Upstox

Indegene Limited IPO Review

Indegence Limited IPO was engaged in offering digital-based services for life sciences businesses like biopharmaceuticals, emerging biotech firms, and medical device companies. These services help with various aspects like drug development, clinical trials, regulatory submissions, pharmacovigilance, complaints management, and sales and marketing of products. Their solutions streamline the process of developing and launching products, as well as boosting sales throughout their lifecycle, making it more efficient and contemporary.

Indegene Limited competitive strengths are Domain expertise in healthcare, Robust digital capabilities and in-house developed technology portfolio, Track record of establishing long standing client relationships, Global delivery model, Track record of creating value through acquisitions.

Indegene Limited Products and Services

Indegene Limited assist biopharmaceutical, emerging biotech, and medical device companies in creating, launching, and enhancing their products in a better, faster, and more up-to-date manner. By combining their knowledge in healthcare, appropriate technology, and flexible operations, they offer a variety of solutions. These solutions strive to achieve personalized, adaptable, and multi-channel experiences for patients and doctors, aligning with their mission to prepare healthcare organizations for the future.

It motivates their team and guides all their actions. Since the beginning, they've been dedicated to updating healthcare practices by combining extensive medical knowledge with suitable technology. In today's digital era, their purpose is more important than ever. They assist life sciences companies throughout the entire process of bringing their products to market, utilizing their comprehensive skills and knowledge.

Financial Overview

The company has a one-of-a-kind way of doing business and dominates its industry globally, bringing in more than 98% of the revenue. It has shown consistent growth in both sales and profits over the reported periods, and the future looks promising for its sector. Looking at the earnings projected for the full year of FY24, the stock seems valued, but given its specialized market position, it's priced reasonably, offering potential gains for investors. This IPO could be a good opportunity for investors looking for medium to long-term benefits.